These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 31832637)

  • 1. Cotrimoxazole Prophylaxis Selects for Antimicrobial Resistance in Human Immunodeficiency Virus-Exposed, Uninfected Infants.
    Bourke CD; Evans C
    Clin Infect Dis; 2020 Dec; 71(11):2869-2871. PubMed ID: 31832637
    [No Abstract]   [Full Text] [Related]  

  • 2. Cotrimoxazole Prophylaxis Increases Resistance Gene Prevalence and α-Diversity but Decreases β-Diversity in the Gut Microbiome of Human Immunodeficiency Virus-Exposed, Uninfected Infants.
    D'Souza AW; Moodley-Govender E; Berla B; Kelkar T; Wang B; Sun X; Daniels B; Coutsoudis A; Trehan I; Dantas G
    Clin Infect Dis; 2020 Dec; 71(11):2858-2868. PubMed ID: 31832638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cotrimoxazole prophylaxis was associated with enteric commensal bacterial resistance among HIV-exposed infants in a randomized controlled trial, Botswana.
    Powis KM; Souda S; Lockman S; Ajibola G; Bennett K; Leidner J; Hughes MD; Moyo S; van Widenfelt E; Jibril HB; Makhema J; Essex M; Shapiro RL
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29119726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised controlled trial testing the effect of cotrimoxazole prophylaxis on morbidity and mortality outcomes in breastfed HIV-exposed uninfected infants: study protocol.
    Coutsoudis A; Daniels B; Moodley-Govender E; Ngomane N; Zako L; Spooner E; Kiepiela P; Reddy S; Kuhn L; Ramjee G
    BMJ Open; 2016 Jul; 6(7):e010656. PubMed ID: 27406638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strain-level analysis of gut-resident pro-inflammatory viridans group Streptococci suppressed by long-term cotrimoxazole prophylaxis among HIV-positive children in Zimbabwe.
    Gough EK; Bourke CD; Berejena C; Shonhai A; Bwakura-Dangarembizi M; Prendergast AJ; Manges AR
    Gut Microbes; 2020 Jul; 11(4):1104-1115. PubMed ID: 32024435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescription of Antibacterial Drugs for HIV-Exposed, Uninfected Infants, Malawi, 2004-2010.
    Ewing AC; Davis NL; Kayira D; Hosseinipour MC; van der Horst C; Jamieson DJ; Kourtis AP;
    Emerg Infect Dis; 2019 Jan; 25(1):103-12. PubMed ID: 30561313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cotrimoxazole prophylaxis and risk of severe anemia or severe neutropenia in HAART-exposed, HIV-uninfected infants.
    Dryden-Peterson S; Jayeoba O; Hughes MD; Jibril H; McIntosh K; Modise TA; Asmelash A; Powis KM; Essex M; Shapiro RL; Lockman S
    PLoS One; 2013; 8(9):e74171. PubMed ID: 24086319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members.
    Mermin J; Lule J; Ekwaru JP; Downing R; Hughes P; Bunnell R; Malamba S; Ransom R; Kaharuza F; Coutinho A; Kigozi A; Quick R
    AIDS; 2005 Jul; 19(10):1035-42. PubMed ID: 15958834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cotrimoxazole guidelines for infants who are HIV-exposed but uninfected: a call for a public health and ethics approach to the evidence.
    Daniels B; Kuhn L; Spooner E; Mulol H; Goga A; Feucht U; Essack SY; Coutsoudis A
    Lancet Glob Health; 2022 Aug; 10(8):e1198-e1203. PubMed ID: 35839818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brief Report: Cessation of Long-Term Cotrimoxazole Prophylaxis in HIV-Infected Children Does Not Alter the Carriage of Antimicrobial Resistance Genes.
    Francis F; Gough EK; Edens TJ; Berejena C; Bwakura-Dangarembizi M; Shonhai A; Nathoo KJ; Glass M; Gibb DM; Prendergast AJ; Manges AR
    J Acquir Immune Defic Syndr; 2020 Dec; 85(5):601-605. PubMed ID: 32852361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cotrimoxazole on non-susceptibility to antibiotics in Streptococcus pneumoniae carriage isolates among HIV-infected mineworkers in South Africa.
    Pemba L; Charalambous S; von Gottberg A; Magadla B; Moloi V; Seabi O; Wasas A; Klugman KP; Chaisson RE; Fielding K; Churchyard GJ; Grant AD
    J Infect; 2008 Mar; 56(3):171-8. PubMed ID: 18262281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of co-trimoxazole prophylaxis on morbidity and mortality of HIV-exposed, HIV-uninfected infants in South Africa: a randomised controlled, non-inferiority trial.
    Daniels B; Coutsoudis A; Moodley-Govender E; Mulol H; Spooner E; Kiepiela P; Reddy S; Zako L; Ho NT; Kuhn L; Ramjee G
    Lancet Glob Health; 2019 Dec; 7(12):e1717-e1727. PubMed ID: 31708152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged Cotrimoxazole Prophylaxis Has No Impact on Child Growth in the First Two Years of Life: Findings from a Randomized Controlled Trial in Botswana.
    Mussa A; Powis KM; Lockman S; Ajibola G; Morroni C; Smeaton L; Mmalane M; Makhema J; Shapiro RL
    J Pediatr; 2022 Jul; 246():266-270.e2. PubMed ID: 35351531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does cotrimoxazole prophylaxis in HIV patients increase the drug resistance of pneumococci? A comparative cross-sectional study in southern Ethiopia.
    Seid M; Beyene G; Alemu Y; Workalemahu B; Delbo M; Taddesse D; Biresaw G; Manilal A
    PLoS One; 2020; 15(12):e0243054. PubMed ID: 33284828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children.
    Mulenga V; Ford D; Walker AS; Mwenya D; Mwansa J; Sinyinza F; Lishimpi K; Nunn A; Gillespie S; Zumla A; Chintu C; Gibb DM;
    AIDS; 2007 Jan; 21(1):77-84. PubMed ID: 17148971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with coverage of cotrimoxazole prophylaxis in HIV-exposed children in South Africa.
    Moodley D; Reddy L; Mahungo W; Masha R
    PLoS One; 2013; 8(5):e63273. PubMed ID: 23667599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation.
    Bourke CD; Gough EK; Pimundu G; Shonhai A; Berejena C; Terry L; Baumard L; Choudhry N; Karmali Y; Bwakura-Dangarembizi M; Musiime V; Lutaakome J; Kekitiinwa A; Mutasa K; Szubert AJ; Spyer MJ; Deayton JR; Glass M; Geum HM; Pardieu C; Gibb DM; Klein N; Edens TJ; Walker AS; Manges AR; Prendergast AJ
    Sci Transl Med; 2019 Apr; 11(486):. PubMed ID: 30944164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective efficacy of prolonged co-trimoxazole prophylaxis in HIV-exposed children up to age 4 years for the prevention of malaria in Uganda: a randomised controlled open-label trial.
    Homsy J; Dorsey G; Arinaitwe E; Wanzira H; Kakuru A; Bigira V; Muhindo M; Kamya MR; Sandison TG; Tappero JW
    Lancet Glob Health; 2014 Dec; 2(12):e727-36. PubMed ID: 25433628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does trimethoprim-sulfamethoxazole prophylaxis for HIV induce bacterial resistance to other antibiotic classes? Results of a systematic review.
    Sibanda EL; Weller IV; Hakim JG; Cowan FM
    Clin Infect Dis; 2011 May; 52(9):1184-94. PubMed ID: 21467024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of daily cotrimoxazole on clinical malaria and asymptomatic parasitemias in HIV-exposed, uninfected infants.
    Davis NL; Barnett EJ; Miller WC; Dow A; Chasela CS; Hudgens MG; Kayira D; Tegha G; Ellington SR; Kourtis AP; van der Horst C; Jamieson DJ; Juliano JJ
    Clin Infect Dis; 2015 Aug; 61(3):368-74. PubMed ID: 25900173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.